Grapefruit juice-drug interactions
- PMID:9723817
- PMCID: PMC1873672
- DOI: 10.1046/j.1365-2125.1998.00764.x
Grapefruit juice-drug interactions
Abstract
The novel finding that grapefruit juice can markedly augment oral drug bioavailability was based on an unexpected observation from an interaction study between the dihydropyridine calcium channel antagonist, felodipine, and ethanol in which grapefruit juice was used to mask the taste of the ethanol. Subsequent investigations showed that grapefruit juice acted by reducing presystemic felodipine metabolism through selective post-translational down regulation of cytochrome P450 3A4 (CYP3A4) expression in the intestinal wall. Since the duration of effect of grapefruit juice can last 24 h, repeated juice consumption can result in a cumulative increase in felodipine AUC and Cmax. The high variability of the magnitude of effect among individuals appeared dependent upon inherent differences in enteric CYP3A4 protein expression such that individuals with highest baseline CYP3A4 had the highest proportional increase. At least 20 other drugs have been assessed for an interaction with grapefruit juice. Medications with innately low oral bioavailability because of substantial presystemic metabolism mediated by CYP3A4 appear affected by grapefruit juice. Clinically relevant interactions seem likely for most dihydropyridines, terfenadine, saquinavir, cyclosporin, midazolam, triazolam and verapamil and may also occur with lovastatin, cisapride and astemizole. The importance of the interaction appears to be influenced by individual patient susceptibility, type and amount of grapefruit juice and administration-related factors. Although in vitro findings support the flavonoid, naringin, or the furanocoumarin, 6',7'-dihydroxybergamottin, as being active ingredients, a recent investigation indicated that neither of these substances made a major contribution to grapefruit juice-drug interactions in humans.
Figures




Comment in
- Effect of grapefruit juice on the disposition of omeprazole.Mouly S, Paine MF.Mouly S, et al.Br J Clin Pharmacol. 2001 Aug;52(2):216-7.Br J Clin Pharmacol. 2001.PMID:11488783Free PMC article.No abstract available.
Similar articles
- Grape fruit juice-drug interactions.Arayne MS, Sultana N, Bibi Z.Arayne MS, et al.Pak J Pharm Sci. 2005 Oct;18(4):45-57.Pak J Pharm Sci. 2005.PMID:16380358Review.
- Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans.Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR.Bailey DG, et al.Clin Pharmacol Ther. 1998 Sep;64(3):248-56. doi: 10.1016/S0009-9236(98)90173-4.Clin Pharmacol Ther. 1998.PMID:9757148Clinical Trial.
- Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.Fuhr U.Fuhr U.Drug Saf. 1998 Apr;18(4):251-72. doi: 10.2165/00002018-199818040-00002.Drug Saf. 1998.PMID:9565737Review.
- Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins.Malhotra S, Bailey DG, Paine MF, Watkins PB.Malhotra S, et al.Clin Pharmacol Ther. 2001 Jan;69(1):14-23. doi: 10.1067/mcp.2001.113185.Clin Pharmacol Ther. 2001.PMID:11180034Clinical Trial.
- Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB.Lown KS, et al.J Clin Invest. 1997 May 15;99(10):2545-53. doi: 10.1172/JCI119439.J Clin Invest. 1997.PMID:9153299Free PMC article.
Cited by
- Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.Lin HL, Kenaan C, Hollenberg PF.Lin HL, et al.Drug Metab Dispos. 2012 May;40(5):998-1006. doi: 10.1124/dmd.112.044560. Epub 2012 Feb 16.Drug Metab Dispos. 2012.PMID:22344702Free PMC article.
- Marginal increase of sunitinib exposure by grapefruit juice.van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den Hartigh J, König-Quartel JM, Guchelaar HJ, Gelderblom H.van Erp NP, et al.Cancer Chemother Pharmacol. 2011 Mar;67(3):695-703. doi: 10.1007/s00280-010-1367-0. Epub 2010 May 29.Cancer Chemother Pharmacol. 2011.PMID:20512335Free PMC article.Clinical Trial.
- Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) that Modulate Drug Membrane Permeation and Pre-Systemic Metabolism.Peterson B, Weyers M, Steenekamp JH, Steyn JD, Gouws C, Hamman JH.Peterson B, et al.Pharmaceutics. 2019 Jan 16;11(1):33. doi: 10.3390/pharmaceutics11010033.Pharmaceutics. 2019.PMID:30654429Free PMC article.Review.
- Herbal bioactivation: the good, the bad and the ugly.Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ.Zhou S, et al.Life Sci. 2004 Jan 9;74(8):935-68. doi: 10.1016/j.lfs.2003.09.035.Life Sci. 2004.PMID:14672753Free PMC article.Review.
- The influence of Nifadin, Niprisan and Niprd/92/001/1-1 (AM-1) on the pharmacokinetics of metronidazole in rats.Bakare-Odunola MT, Mustapha KB, Garba M, Obodozie OO, Enemali IS.Bakare-Odunola MT, et al.Eur J Drug Metab Pharmacokinet. 2010 Sep;35(1-2):55-8. doi: 10.1007/s13318-010-0008-7.Eur J Drug Metab Pharmacokinet. 2010.PMID:21495267
References
- Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokin. 1994;26:91–98. - PubMed
- Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JMO. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med. 1989;12:357–362. - PubMed
- Edgar B, Regardh CG, Johnsson G, et al. Felodipine kinetics in healthy man. Clin Pharmacol Ther. 1985;38:205–211. - PubMed
- Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion—pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997;52:139–145. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources